| abstract |
The present invention is directed to stable formulations of modified antibodies, each comprising an antibody fragment in an aqueous solution covalently attached to at least one nonproteinaceous polymer, such as poly(ethyleneglycol), through a succinimide moiety. CDP870 is an example of one such modified antibody. The formulations of the present invention include a buffer that maintains the solution at a pH of 3.5 to about 6, wherein all components of the modified antibody, including a succinimide ring of the succinimide moiety, are stable. |